Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 332-337

  Usuda, Jitsuo ^a   Ichinose, Shuji ^a   Ishizumi, Taichirou ^a   Ohtani, Keishi ^a   Inoue, Tatsuya ^a   Saji, Hisashi ^a   Kakihana, Masatoshi ^a   Kajiwara, Naohiro ^a   Uchida, Osamu ^a   Nomura, Masaharu ^a   Ohira, Tatsuo ^a   Ikeda, Norihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Breast cancer resistant protein (BCRP); Klotho; MDR; MRP1; Small cell lung cancer

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IRINOTECAN; KLOTHO PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

AGED; CHEMOTHERAPY, ADJUVANT; EARLY DETECTION OF CANCER; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

EID: 80053643828     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.004     Document Type: Article

References (26)

1. Vallieres E., Shepherd F.A., Crowley J., Houtte P.V., Postmus P.E., Carney D., et al. The IASLC lung cancer staging project, proposals regarding to relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4:1049-1059.
2. Devesa S.S., Bray F., Vizcaino A.P., Parkin D.M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005, 117:294-299.
3. Simon G.R., Turrisi A. Management of small cell lung cancer. ACCP-evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:324-339.
4. British Thoracic Society Society of Cardiothoracic Sugeons of Great Britain and Ireland Working Party. Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001, 56:89-108.
5. Lucchi M., Chella A., Melfi F., Dini P., libaldi C., Fontanini G., et al. Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg 1997, 12:689-693.
6. Ihde D., Souhami B., Comis R., GregorA, Johnson B., Murray N., et al. Small cell lung cancer. Lung Cancer 1997, 17:19-21.
7. Janne P.A., Freidlin B., Saxman S., Johnson D.H., Livingston R.B., Shepherd F.A., et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002, 95:1528-1538.
8. Yu J.B., Decker R.H., Detterbeck F., Wilson L.D. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010, 5:215-219.
9. Shepherd F.A. Surgery for limited stage small cell lung cancer. J Thorac Oncol 2010, 5:147-149.
10. Merkle N.M., Mickisch G.H., Kayser K., Drings P., Vogt-Moykopfl Surgical resection and adjuvant chemotherapy for small cell carcinoma. Thorac Cardiovasc Surg 1986, 34:39-42.
11. Lad T., Piantadosi S., Thomas P., Payne D., Ruckdeschel J., Giaccone G., et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106:320-323.
12. Chiappori A.A., Zheng Z., Chen T., Rawal B., Schell M.J., Mullaney B.P., et al. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol 2010, 5:484-490.
13. Kim Y.H., Ishii G., Goto K., Ota S., Kubota K., Murata Y., et al. Expression of breast cancer resistant protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 2009, 65:105-111.
14. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:1691-1697.
15. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
16. Skov B.G., Holm B., Erreboe A., Skov T., Mellemgaard A. ERCC1 and Ki67 small cell lung carcinoma and other neuroendocrine tumors of the lung. J Thorac Oncol 2010, 5:453-459.
17. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
18. Matsumura Y., Aizawa H., Shiraki-lida T., Nagai R., Kuro-o M., Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 1998, 242:626-630.
19. Kurosu H., Yamamoto M., Clark J.D., Pastor J.V., Nandi A., Gurnani P., et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309:1829-1833.
20. Wolf I., Laitman Y., Rubinek T., Abramovitz I., Been R., Kuro-o M., et al. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 2010, 29:26-33.
21. Lee J., Jeong D.J., Kim J., Lee S., Park J.-H., Chang B., et al. The anti-aging gene Klotho is a novel target for epigeneticsilencing in human cervical carcinoma. Mol Cancer 2010, 9:109-118.
22. Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H, et al. Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer; in press, doi:10.1016/j.lungcan.2010.10.008.
23. Dhillon T., Mauri F.A., Bellezza G., Cagini L., Barbareschi M., North B.V., et al. Overexpression of the mammalian target rapamycin; a novel biomarker for poor survival in resected early stage non small cell lung cancer. J Thorac Oncol 2010, 5:314-319.
24. Lee Y.J., Kim H.T., Han J.Y., Yun T., Lee G.K., Kim H.Y., et al. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. J Thorac Oncol 2010, 5:361-368.
25. Nakao M., Yoshida J., lshii G., Hishida T., Nishimura M., Nagai K., et al. Prognostic impact of node involvement pattern in pulmonary pN1 squamous cell carcinoma patients. J Thorac Oncol 2010, 5:504-509.
26. Ou S.H., Ziogas A., Zell J.A. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol 2010, 5:420-427.